Guangzhou and London – May 22, 2025 – Bio-Thera Solutions,Ltd (688177:SH), a commercial-stage biopharmaceutical company developing apipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC,along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. today announcedtha...
DetailsTheclinical comparative study met its primary endpoint and showed similar efficacyand comparable safety profile in patients with moderate to severe plaque psoriasis GUANGZHOU,China, November 29, 2023 /PRNewswire/ -- Bio-Thera Solutions, Ltd. (688177:SH),a commercial-stage biopharmaceutical company d...
GUANGZHOU,China, October 24, 2023 -- Bio-Thera Solutions, Ltd (688177:SH), acommercial-stage biopharmaceutical company developing a pipeline of biosimilarsand innovative assets, announced that the National Health Surveillance Agency(“ANVISA”) published the approval of the certification of good m...
TOFIDENCE is Bio-Thera’s first productapproved by USFDA. TOFIDENCE is the first monoclonal antibodydrug researched, developed, and manufactured by a Chinese pharmaceuticalcompany to receive FDA approval in the United States TOFIDENCE is the first biosimilar toActemra approved by USFDA GUANGZHOU, C...
